Skip to main content
SpringerLink
Log in

Chemotherapy Induced Peripheral Neuropathies (CIPNs): A Biobehavioral Approach

  • Chapter
  • First Online:
Biobehavioral Approaches to Pain

  • 924 Accesses

Abstract

Pain is a prevalent symptom in patients with cancer. Chemotherapy Induced Peripheral Neuropathies (CIPNs), as a type of cancer related pain, are an increasingly common neuropathic pain syndrome. In this paper, we offer a biobehavioral approach to understanding the development and perhaps the maintenance of CIPNs. First, CIPNs are defined. This is followed by a description of the epidemiology, symptoms, and barriers associated with CIPNs. Following important research from the fields of pain, behavior and psychoneuroimmunology (PNI), we suggest that injury to peripheral nerves after chemotherapeutic treatments initiates immune to brain communication, which further modulates the biological mechanisms through which life experiences and behavior reinforce and likely perpetuate the experience of CIPN.

“I moan, I try to speak and my soul feels suffocated…”

The 77th Psalm

“The worse pain a person can suffer: to have insight into much and power over nothing.”

Herodotus

“Give me life, Give me pain, Give me myself again.”

Tori Amos

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Hewitt,M, Greenfield,S, Stovall, E. (Eds). Cancer Patient to Cancer Survivor: Lost in Transition. IOM Report, National Academies Press, 2005.

    Google Scholar 

  2. Mao JJ, Armstrong K, Bowman MA, Xie SX, Kadakia R, Farrar JT. Symptom burden among cancer survivors: impact of age and comorbidity. Journal of the American Board of Family Medicine. 2007;20(5):434–43.

    Article  PubMed  Google Scholar 

  3. von Eschenbach AC. Progress with a purpose: eliminating suffering and death due to cancer. Oncology (Williston Park). 2006;20(13):1691–6.

    Google Scholar 

  4. Mako C, Galek K, Poppito SR. J Spiritual pain among patients with advanced cancer in palliative care. Palliative Medicine 2006 Oct;9(5):1106–13.

    Article  PubMed  Google Scholar 

  5. Shaiova L. Difficult pain syndromes: bone pain, visceral pain, and neuropathic pain. Cancer Journal 2006;12(5):330–40.

    Article  CAS  Google Scholar 

  6. Mystakidou K, Tsilika E, Parpa E, Katsouda E, Galanos A, Vlahos L. Psychological distress of patients with advanced cancer: influence and contribution of pain severity and pain interference. Cancer Nursing 2006;29(5):400–5.

    Article  PubMed  Google Scholar 

  7. Trask PC, Teno JM, Nash J. Transitions of care and changes in distressing pain. Journal of Pain and Symptom Management 2006;32(2):104–9).

    Article  PubMed  Google Scholar 

  8. Mantyh PW. Cancer pain and its impact on diagnosis, survival and quality of life. Nature Reviews Neuroscience 2006;7(10):797–809.

    Article  PubMed  CAS  Google Scholar 

  9. Wickham R. Chemotherapy-induced peripheral neuropathy: a review and implications for oncology nursing practice. Clinical Journal of Oncology Nursing 2007;11(3):361–76

    Article  PubMed  Google Scholar 

  10. Stillman M, Cata JP. Management of chemotherapy-induced peripheral neuropathy. Current Pain and Headache Reports 2006 Aug;10(4):279–87.

    Article  PubMed  Google Scholar 

  11. Cavaletti G, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity. Expert Opin Drug Saf. 2004;3(6):535–46.

    Article  PubMed  CAS  Google Scholar 

  12. Dunlap B, Paice JA. Chemotherapy-induced peripheral neuropathy: A need for standardization in measurement. Journal of Supportive Oncology 2006 Sep;4(8):398–9.

    PubMed  Google Scholar 

  13. Paice JA. Chemotherapy-Induced Peripheral Neuropathy: A Dangerous but Understudied Syndrome. Pain Management SIG Newsletter 2008;17(1). http://onsopcontent.ons.org/Publications/SigNewsletters/pm/pm17.1.html Date accessed: 01/01/2008

  14. Kannarkat G, Lasher EE, Schiff D. Neurologic complications of chemotherapy agents. Current Opinion in Neurology. 2007 Dec;20(6):719–25.

    PubMed  CAS  Google Scholar 

  15. Paice, JA. Peripheral neuropathy: Experimental findings, clinical approaches. Supportive Oncology 2007;5(2), 61–63.

    Google Scholar 

  16. Hausheer, F.H., Schilsky, R.L., Bain, S., Berghorn, E.J., Lieberman, F. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Seminars in Oncology 2006;33, 15–49.

    Article  PubMed  CAS  Google Scholar 

  17. Dougherty, P. M., Cata, J. P., Cordella, J. V., Burton, A. Weng, H. R. Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients. Pain 2004;109, 132–142.

    Article  PubMed  CAS  Google Scholar 

  18. Postma, T. J. , Vermorken, J. B. , Liefting, A. J. , Pinedo, H. M. Heimans, J. J. Paclitaxel-induced neuropathy. Annals of Oncology 1995;6, 489–494.

    PubMed  CAS  Google Scholar 

  19. Benoliel R, Epstein J, Eliav E, Jurevic R, Elad S. Orofacial pain in cancer: part I – mechanisms. Journal of Dental Research 2007;86(6):491–505.

    Article  PubMed  CAS  Google Scholar 

  20. Verstappen, C. C. , Postma, T. J. , Hoekman, K. Heimans, J. J. Peripheral neuropathy due to therapy with paclitaxel, gemcitabine, and cisplatin in patients with advanced ovarian cancer. Journal of Neurooncology 2003;63, 201–205.

    Article  CAS  Google Scholar 

  21. Cavaletti G, Bogliun G, Marzorati L, Zincone A, Piatti M, Colombo N, Franchi D. Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy. Annals of Oncology 2004;15(9):1439–42.

    Article  PubMed  CAS  Google Scholar 

  22. Moore, RJ. Transportation Issues in Patients with Cancer. (in preparation, 2008).

    Google Scholar 

  23. Moore RJ, Spiegel D. Cancer Culture and Communication. Springer, NY, 2004.

    Google Scholar 

  24. England JD, Asbury AK. Peripheral neuropathy. Lancet 2004;363(9427):2151–61.

    Article  PubMed  Google Scholar 

  25. Postma TJ, Heimans JJ. Grading of chemotherapy-induced peripheral neuropathy. Annals of Oncology 2000 May;11(5):509–13]

    Article  PubMed  CAS  Google Scholar 

  26. Postma TJ, Hoekman K, van Riel JM, Heimans JJ, Vermorken JB. Peripheral neuropathy due to biweekly paclitaxel, epirubicin and cisplatin in patients with advanced ovarian cancer. Journals of Neurooncology 1999;45(3):241–6.

    Article  CAS  Google Scholar 

  27. Postma TJ, Heimans JJ, Luykx SA, van Groeningen CJ, Beenen LF, Hoekstra OS, Taphoorn MJ, Zonnenberg BA, Klein M, Vermorken JB. A phase II study of paclitaxel in chemonaïve patients with recurrent high-grade glioma. Annals of Oncology 2000 Apr;11(4):409–13.

    Article  PubMed  CAS  Google Scholar 

  28. Asbury AK. Peripheral neuropathy. Lancet. 2004;363(9427):2151–61.

    Article  PubMed  Google Scholar 

  29. Scholz J, Woolf CJ. The neuropathic pain triad: neurons, immune cells and glia. Nature Neuroscience 2007;10(11):1361–1368.

    Article  PubMed  CAS  Google Scholar 

  30. Cavaletti G, Zanna C. Current status and future prospects for the treatment of chemotherapy-induced peripheral neurotoxicity. European Journal of Cancer 2002 Sep;38(14):1832–7.

    Article  PubMed  CAS  Google Scholar 

  31. Bogduk, M, eds. Classification of Chronic Pain, 2nd Edition, International Association for the Study of Pain Task Force on Taxonomy. Seattle, Wash: IASP Press; 1994:209–214.

    Google Scholar 

  32. Gatchel RJ, Peng YB, Peters ML, Fuchs PN, Turk DC. The biopsychosocial approach to chronic pain: scientific advances and future directions. Psychological Bulletin 2007;133(4):581–624.

    Article  PubMed  Google Scholar 

  33. Argyriou AA, Polychronopoulos P, Koutras A, Iconomou G, Iconomou A, Kalofonos HP,Chroni E. Peripheral neuropathy induced by administration of cisplatin- andpaclitaxel-based chemotherapy. Could it be predicted? Support Care in Cancer 2005 Aug;13(8):647–51.

    Article  Google Scholar 

  34. Ziegler D, Nowak H, Kempler P, Vargha P, Low PA. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: A meta-analysis Diabetic Medicine 2004;21:114–121.

    Article  PubMed  CAS  Google Scholar 

  35. Almadrones L, McGuire DB, Walczak JR, Florio CM, Tian C. Psychometric evaluation of two scales assessing functional status and peripheral neuropathy associated with chemotherapy for ovarian cancer: A Gynecologic Oncology Group study. Oncology Nursing Forum 2004;31:615–623.

    Article  PubMed  Google Scholar 

  36. Almadrones LA. Neurologic complications. In J.M. Yasko (Ed.), Nursing management of symptom associated with chemotherapy. Meniscus Health Care Communications, West Conshohocken, PA. 2001, 5th ed., pp. 215–230.

    Google Scholar 

  37. Almadrones LA, Arcot, R. Patient guide to peripheral neuropathy. Oncology Nursing Forum 1999;26:1359–1361.

    PubMed  CAS  Google Scholar 

  38. Aloe L, Manni L, Porperzi F, De Santis S, Fiore M. Evidence that nerve growth factor promotes the recovery of peripheral neuropathy induced in mice by cisplatin: Behavioral, structural, and biochemical analysis. Autonomic Neuroscience-Basic and Clinical 2000;86:84–93.

    Article  CAS  Google Scholar 

  39. Argoff CE, Katz N, Backonja, M. Treatment of postherpetic neuralgia: A review of therapeutic options. Journal of Pain and Symptom Management 2004;28:396–411.

    Article  PubMed  Google Scholar 

  40. Argyriou AA, Chroni E, Koutras A, Ellul J, Papapetropoulos S, Katsoulas G, et al. Vitamin E for prophylaxis against chemotherapy-induced neuropathy. A randomized controlled trial. Neurology 2005;64:26–31.

    PubMed  CAS  Google Scholar 

  41. Argyriou AA, Polychronopoulos P, Koustra A, Iconomou G, Gourzis P, Assimakopoulos K, et al. Is advanced age associated with increased incidence and severity of chemotherapy-induced peripheral neuropathy? Supportive Care in Cancer 2006;14:223–229

    Article  PubMed  Google Scholar 

  42. Armstrong T, Almadrones L, Gilbert MR. Chemotherapy-induced peripheral neuropathy. Oncology Nursing Forum 2005;32:305–311.

    Article  PubMed  Google Scholar 

  43. Authier N, Gillet JP, Fialip J, Eschalier A, Coudore F. An animal model of nociceptive peripheral neuropathy following repeated cisplatin injections. Experimental Neurology 2003;182:12–20.

    Article  PubMed  CAS  Google Scholar 

  44. Backonja MM, Serra J. Pharmacologic management part 1: Better-studied neuropathic pain diseases. Pain Medicine 2004;5(Suppl. 1), S28–S47.

    Article  PubMed  Google Scholar 

  45. Beydoun A, Backonja MM. Mechanistic stratification of antineuralgic agents. Journal of Pain and Symptom Management 2003;25(5, Suppl.), S18–S30

    Article  PubMed  CAS  Google Scholar 

  46. Cassidy J, Bjarnason GA, Hickish T, Topham C, Provencio M, Bodoky G, et al. Randomized double blind placebo controlled phase III study assessing the efficacy of xaliproden in reducing the cumulative peripheral sensory neuropathy induced by the oxaliplatin and 5-FU/LV combination (FOLFOX4) in first line treatment of patients with metastatic colorectal cancer, 2006, [Abstract 229].

    Google Scholar 

  47. Cavaletti G, Petruccioli MG, Marmiroli P, Rigolio R, Galbiati S, Zoia C, et al. Circulating nerve growth factor level changes during oxaliplatin treatment-induced neurotoxicity in the rat. Anticancer Research 2002;22(6C):4199–4204.

    PubMed  CAS  Google Scholar 

  48. Boehmke MM, Dickerson SS. Symptom, symptom experiences, and symptom distress encountered by women with breast cancer undergoing current treatment modalities. Cancer Nursing 2005;28:382–389.

    Article  PubMed  Google Scholar 

  49. Cascinu S, Catalano V, Cordella L, Lubianca R, Giordano P, Baldelli AM, et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: A randomized, double-blind, placebo-controlled trial. Journal of Clinical Oncology 2002;20:3478–3483

    Article  PubMed  CAS  Google Scholar 

  50. Cassidy J, Misset JL. Oxaliplatin-related side effects: Characteristics and management. Seminars in Oncology 2002;29(Suppl. 15):11–20.

    Article  PubMed  CAS  Google Scholar 

  51. Cersosimo RJ. Oxaliplatin-associated neuropathy: A review. Annals of Pharmacotherapy 2005;39:128–135.

    Article  PubMed  CAS  Google Scholar 

  52. Chaudhry V, Cornblath DR, Corse A, Freimer M, Simmons-O’Brien E, Vogelsang G. Thalidomide-induced neuropathy. Neurology 2002;59:1872–1875.

    PubMed  CAS  Google Scholar 

  53. Cianfrocca M, Glatters SJ, Bennett GJ, McNicol E, Relias V, Carr D, et al. Peripheral neuropathy in a woman with breast cancer. Journal of Pain 2006;7:2–10.

    Article  PubMed  Google Scholar 

  54. Criscuolo S, Auletta C, Lippi S, Brogi F, Brogi A. Oxcarbazepine (Trileptal®) monotherapy dramatically improves quality of life in two patients with postherpetic neuralgia refractory to carbamazepine and gabapentin. Journal of Pain and Symptom Management 2004;28:535–536.

    Article  PubMed  Google Scholar 

  55. De Santis S, Pace A, Bove L, Cognetti F, Properzi F, Fiore M, et al. Patients treated with antitumor drugs displaying neurological deficits are characterized by a low circulating level of nerve growth factor. Clinical Cancer Research 2000;6:90–95.

    PubMed  Google Scholar 

  56. du Bois A, Schlaich M, Lück HJ, Mollenkopf A, Wechsel U, Rauchholz M, et al. Evaluation of neurotoxicity induced by paclitaxel second- line chemotherapy. Supportive Care in Cancer 1999;7:354–361.

    Article  PubMed  Google Scholar 

  57. Durand JP, Alexandre J, Guillevin L, Goldwasser F. Clinical activity of venlafaxine and topiramate against oxaliplatin-induced disabling permanent neuropathy. Anti-Cancer Drugs 2005;16:587–591.

    Article  PubMed  CAS  Google Scholar 

  58. Fine PG, Miaskowski C, Paice JA. Meeting the challenges in cancer pain management. Journal of Supportive Oncology 2004;2(Suppl. 4):5–22.

    PubMed  Google Scholar 

  59. Frisk P, Stalberg E, Stromberg B, Jakobson A. Painful peripheral neuropathy after treatment with high-dose ifosfamide. Medical and Pediatric Oncology 2001;37:379–382.

    Article  PubMed  CAS  Google Scholar 

  60. Gamelin E, Gamelin L, Bossi L, Quasthoff S. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: Current management and development of preventive measures. Seminars in Oncology 2002;29(Suppl. 15):21–33.

    Article  PubMed  CAS  Google Scholar 

  61. Gamelin L, Boisdron-Celle M, Delva R, Guérin-Meyer V, Ifrah N, Morel A, et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: A retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clinical Cancer Research 2004;10:4055–4061. Gornet JM, Savier E, Lokiec F, Cvitkovic E, Misset JL, Goldwasser F. Exacerbation of oxaliplatin neurosensory toxicity following surgery. Annals of Oncology 2002;13:1315–1318.

    Google Scholar 

  62. Grothey A. Oxaliplatin—Safety profile: Neurotoxicity. Seminars in Oncology 2003;30(Suppl. 15):5–13.

    Article  PubMed  CAS  Google Scholar 

  63. HughesRA. Peripheral neuropathy. BMJ 2002;324:466–469

    Google Scholar 

  64. Lehky TJ, Leonard GD, Wilson RH, Grem JL, Floeter MK. Oxaliplatin-induced neurotoxicity: Acute hyperexcitability and chronic neuropathy. Muscle and Nerve 2004;29:287–292.

    Article  CAS  Google Scholar 

  65. Grolleau F, Gamelin L, Boisdron-Celle M, Lapied B, Pelhate M, Gamelin E. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels Journal of Neurophysiology 2001;85:2293–2297

    PubMed  CAS  Google Scholar 

  66. Lazo G, Kantarjian H, Estey E, Thomas D, O’Brien S, Cortes J. Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia. Cancer 2003;97:2218–2224.

    Article  PubMed  CAS  Google Scholar 

  67. Lenz G, Hacker UT, Kern W, Schalhorn A, Hiddemann W Adverse reactions to oxaliplatin: A retrospective study of 25 patients treated in one institution. Anti-Cancer Drugs 2003;14:731–733.

    Article  PubMed  CAS  Google Scholar 

  68. Moore DH, Donnelly J, McGuire WP, Almadrones L, Cella DF, Herzog TJ, et al. Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel induced neurotoxicity: A phase II study of the Gynecologic Oncology Group. Journal of Clinical Oncology 2003;21:4207–4213.

    Article  PubMed  CAS  Google Scholar 

  69. Nail LM. Long-term persistence of symptoms. Seminars in Oncology Nursing 2001;17:249–254.

    Article  PubMed  CAS  Google Scholar 

  70. Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Seminars in Oncology 2006;33:15–49.

    Article  PubMed  CAS  Google Scholar 

  71. Leonard GD, Wright MA, Quinn MG, Fioravanti S, Harold N, Schuler B, et al. Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer. British Medical Journal of Cancer 2005;5:116–126.

    Google Scholar 

  72. Marrs J, Newton S. Updating your peripheral neuropathy “know-how.” Clinical Journal of Oncology Nursing 2003;7:299–303.

    Article  PubMed  Google Scholar 

  73. Ocean AJ, Vahdat LT. Chemotherapy-induced peripheral neuropathy: Pathogenesis and emerging therapies. Supportive Care in Cancer 2004;12:619–625.

    PubMed  Google Scholar 

  74. Openshaw H, Beamon K, Synold TW, Longmate J, Statkin NE, Doroshow JH, et al. Neurophysiological study of peripheral neuropathy after high-dose paclitaxel: Lace of neuroprotective effect of amifostine. Clinical Cancer Research 2004;10:461–467.

    Article  PubMed  CAS  Google Scholar 

  75. Paice JA. Mechanisms and management of neuropathic pain in cancer. Supportive Oncology 2003;1:107–112.

    PubMed  Google Scholar 

  76. Polomano RC, Bennett GJ. Chemotherapy-evoked painful peripheral neuropathy. Pain Medicine 2001;2:8–14.

    Article  PubMed  CAS  Google Scholar 

  77. Polomano RC, Farrar JT. Pain and neuropathy in cancer survivors. American Journal of Nursing 2006;106(3, Suppl.): 39–47.

    PubMed  Google Scholar 

  78. Poncelet AN. An algorithm for the evaluation of peripheral neuropathy. American Family Physician 1998;57:755–764.

    PubMed  CAS  Google Scholar 

  79. Postma TJ, Heimans JJ. Grading of chemotherapy-induced peripheral neuropathy. Annals of Oncology 2000;11:509–513.

    Article  PubMed  CAS  Google Scholar 

  80. Postma TJ, Heimans JJ, Muller MJ, Ossenkoppele GJ, Vermorken JB, Aaronson NK. Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Annals of Oncology 1998;9:739–744.

    Article  PubMed  CAS  Google Scholar 

  81. Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. Journal of Neurology 2002;249:9–17.

    Article  PubMed  CAS  Google Scholar 

  82. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. New England Journal of Medicine 2003;348:2609–2617.

    Article  PubMed  CAS  Google Scholar 

  83. Saif MW. Oral calcium ameliorating oxaliplatin-induced peripheral neuropathy. Journal of Applied Research 2004;4:576–582.

    PubMed  Google Scholar 

  84. Smith EL, Whedon MK, Bookbinder M. Quality improvement of painful peripheral neuropathy. Seminars in Oncology Nursing 2002;18:36–43.

    Article  PubMed  Google Scholar 

  85. Sorich J, Taubes B, Wagner A, Hochster H. Oxaliplatin: Practical guidelines for administration. Clinical Journal of Oncology Nursing 2004;8:251–256.

    Article  PubMed  Google Scholar 

  86. Storstein A, Vedeler CA. Neurological symptoms as the first signs of cancer: Paraneoplastic encephalomyelitis and sensory neuronopathy. American Journal of Oncology Review 2005;4:31–34.

    Google Scholar 

  87. Susman E. Xaliproden lessens oxaliplatin-mediated neuropathy. Lancet Oncology 2006;7:288.

    Article  PubMed  Google Scholar 

  88. Sweeney CW. Understanding peripheral neuropathy in patients with cancer: Background and patient assessment. Clinical Journal of Oncology Nursing 2002;6:163–166.

    Article  PubMed  Google Scholar 

  89. Taieb S, Trillet-Lenoir V, Rambaud L, Descos L, Freyer G. Lhermitte sign and urinary retention: Atypical presentation of oxaliplatin neurotoxicity in four patients. Cancer 2002;94:2434–2440.

    Article  PubMed  CAS  Google Scholar 

  90. Tournigand C, Cervantes A, Figer A, Lledo G, Flesh M, Buyse M, et al. OPTIMOX1: A randomized study of FOLFOX4 or FOLFOX7 in a stop-and-go fashion in advanced colorectal cancer—A GERCOR study. Journal of Clinical Oncology 2006;24:394–400.

    Article  PubMed  CAS  Google Scholar 

  91. Verstappen CC, Heimans JJ, Hoekman K, Postma TJ. Neurotoxic complication of chemotherapy in patients with cancer: Clinical signs and optimal management. Drugs 2003;63:1549–1563.

    Article  PubMed  CAS  Google Scholar 

  92. Verstappen CC, Koeppen S, Heimans JJ, Huijgens PC, Scheulen ME, Strumberg D, et al. Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening. Neurology 2005;64:1076–1077.

    PubMed  CAS  Google Scholar 

  93. Visovsky C. Chemotherapy-induced peripheral neuropathy. Cancer Investigation 2003;21:439–451.

    Article  PubMed  Google Scholar 

  94. Wampler MA, Hamolsky D, Hamel K, Melisko M, Topp K.S. Case report: Painful peripheral neuropathy following treatment with docetaxel for breast cancer. Clinical Journal of Oncology Nursing 2005;9:189–193.

    Article  PubMed  Google Scholar 

  95. Wilkes GM. Therapeutic options in the management of colon cancer: 2005 update. Clinical Journal of Oncology Nursing 2005;9:31–44.

    Article  PubMed  Google Scholar 

  96. Willis WD. The nervous system. In R.M. Berne M.N. Levy (Eds.), Principles of physiology. Mosby, St. Louis, 2000, pp. 68–94.

    Google Scholar 

  97. Wilson RH, Lehky T, Thomas RR, Quinn MG, Floeter MK, Grem JL. Acute oxaliplatin-induced peripheral nerve hyperexcitability. Journal of Clinical Oncology 2002;20:1767–1774.

    Article  PubMed  CAS  Google Scholar 

  98. Winegarden JD, Mauer AM, Otterson GA, Rudin CM, Villalona-Calero MA, Lanzotti VJ, et al. A phase II study of oxaliplatin and paclitaxel inpatients with advanced non-small-cell lung cancer. Annals of Oncology 2004;15:915–920

    Article  PubMed  CAS  Google Scholar 

  99. Moalem G, Tracey DJ. Immune and inflammatory mechanisms in neuropathic pain. Brain Research Reviews 2006 Aug;51(2):240–64.

    Article  PubMed  CAS  Google Scholar 

  100. Watkins LR, Hutchinson MR, Milligan ED, Maier SF. Listening" and "talking" to neurons: implications of immune activation for pain control and increasing the efficacy of opioids. Brain Research Review 2007;56(1):148–69.

    Article  CAS  Google Scholar 

  101. Watkins LR, Hutchinson MR, Ledeboer A, Wieseler-Frank J, Milligan ED, Maier SF. Norman Cousins Lecture. Glia as the "bad guys": implications for improving clinical pain control and the clinical utility of opioids. Brain, Behavior, and Immunity 2007;21(2):131–46.

    Article  PubMed  CAS  Google Scholar 

  102. Wieseler-Frank J, Jekich BM, Mahoney JH, Bland ST, Maier SF, Watkins LR. A novel immune-to-CNS communication pathway: cells of the meninges surrounding the spinal cord CSF space produce proinflammatory cytokines in response to an inflammatory stimulus. Brain, Behavior, and Immunity 2007;21(5):711–8.

    Article  PubMed  CAS  Google Scholar 

  103. Banks WA, Watkins LR. Mediation of chronic pain: not by neurons alone. Pain 2006 Sep;124(1–2):1–2.

    Article  PubMed  Google Scholar 

  104. Watkins LR, Hutchinson MR, Johnston IN, Maier SF. Glia: novel counter-regulators of opioid analgesia. Trends in Neuroscience 2005;28(12):661–9.

    CAS  Google Scholar 

  105. Wieseler-Frank J, Maier SF, Watkins LR. Central proinflammatory cytokines and pain enhancement. Neurosignals 2005;14(4):166–74.

    Article  PubMed  CAS  Google Scholar 

  106. Milligan ED, Langer SJ, Sloane EM, He L, Wieseler-Frank J, O'Connor K, Martin D, Forsayeth JR, Maier SF, Johnson K, Chavez RA, Leinwand LA, Watkins LR. Controlling pathological pain by adenovirally driven spinal production of the anti-inflammatory cytokine, interleukin-10. European Journal of Neuroscience 2005;21(8):2136–48.

    Article  PubMed  Google Scholar 

  107. Wieseler-Frank J, Maier SF, Watkins LR. Immune-to-brain communication dynamically modulates pain: physiological and pathological consequences. Brain, Behavior Immunity 2005;19(2):104–11.

    Article  CAS  Google Scholar 

  108. Watkins LR, Maier SF. Immune regulation of central nervous system functions: from sickness responses to pathological pain. Journal of International Medecine 2005;257(2):139–55.

    Article  CAS  Google Scholar 

  109. Watkins LR, Maier SF. Glia: a novel drug discovery target for clinical pain. Nature Reviews Drug Discovery 2003;2(12):973–85.

    Article  PubMed  CAS  Google Scholar 

  110. Dworkin RH, Backonja M, Rowbotham MC, Allen RR, Argoff CR, Bennett GJ,Bushnell MC, Farrar JT, Galer BS, Haythornthwaite JA, Hewitt DJ, Loeser JD, Max MB, Saltarelli M, Schmader KE, Stein C, Thompson D, Turk DC, Wallace MS, Watkins LR, Weinstein SM. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Archives of Neurology 2003;60(11):1524–34.

    Article  PubMed  Google Scholar 

  111. Watkins LR, Milligan ED, Maier SF. Glial proinflammatory cytokines mediate exaggerated pain states: implications for clinical pain. Advances in Experimental Medecine and Biology 2003;521:1–21

    CAS  Google Scholar 

  112. Maier SF, Watkins LR. Immune-to-central nervous system communication and its role in modulating pain and cognition: Implications for cancer and cancer treatment. Brain, Behavior, and Immunity 2003;17 Suppl 1:S125–31.

    Article  PubMed  CAS  Google Scholar 

  113. Watkins LR, Maier SF. Beyond neurons: evidence that immune and glial cells contribute to pathological pain states. Physiological Reviews 2002;82(4):981–1011.

    PubMed  CAS  Google Scholar 

  114. Watkins LR, Milligan ED, Maier SF. Glial activation: a driving force for pathological pain. Trends in Neuroscience 2001 Aug;24(8):450–5.

    Article  CAS  Google Scholar 

  115. White FA, Jung H, Miller RJ. Chemokines and the pathophysiology of neuropathic pain. Proceedings of the National Academy of the Science of the USA. 2007 Dec 18;104(51):20151–8. Epub 2007 Dec 14.

    Google Scholar 

  116. Watkins, LR. Immune and glial regulation of pain Brain, Behavior, and Immunity 2007;21(5):519–521.

    Google Scholar 

  117. Brydon L, Harrison NA, Walker C, Steptoe A, Critchley HD. Peripheral Inflammation is Associated with Altered Substantia Nigra Activity and Psychomotor Slowing in Humans. Biological Psychiatry 2008;63:1022–1029.

    Article  PubMed  CAS  Google Scholar 

  118. Bouchardy C, Rapiti E, Blagojevic S, Vlastos AT, Vlastos G. Older female cancer patients: importance, causes, and consequences of undertreatment. Journal of Clinical Oncology 2007 May 10;25(14):1858–69.

    Article  PubMed  Google Scholar 

  119. Meghani SH, Keane A. Preference for analgesic treatment for cancer pain among African Americans. Journal of Pain and Symptom Management. 2007 Aug;34(2):136–47.

    Article  PubMed  Google Scholar 

  120. Altilio T. Pain and symptom management clinical, policy, and political perspectives. Journal of Psychosocial Oncology 2006;24(1):65–79.

    Article  PubMed  Google Scholar 

  121. Randall-David E, Wright J, Porterfield DS, Lesser G. Barriers to cancer pain management: home-health and hospice nurses and patients. Supportive Care in Cancer 2003 Oct;11(10):660–5.

    Article  PubMed  Google Scholar 

  122. Anderson KO, Richman SP, Hurley J, Palos G, Valero V, Mendoza TR, Gning I, Cleeland CS. Cancer pain management among underserved minority outpatients: perceived needs and barriers to optimal control. Cancer 2002 ;94(8):2295–304.

    Article  PubMed  Google Scholar 

  123. Maxwell T. Cancer pain management in the elderly. Geriatr Nursing 2000 May–Jun;21(3):158–63.

    Article  CAS  Google Scholar 

  124. Portenoy RK, Lesage P. Management of cancer pain. Lancet 1999 May 15;353(9165):1695–700

    Article  PubMed  CAS  Google Scholar 

  125. Cleeland CS. Undertreatment of cancer pain in elderly patients. The Journal of the American Medical Association 1998 Jun 17;279(23):1914–5.

    Article  CAS  Google Scholar 

  126. Rich BA. A legacy of silence: bioethics and the culture of pain. Journal of Medical Humanities 1997 Winter;18(4):233–59.

    Article  PubMed  Google Scholar 

  127. Grossman SA. Undertreatment of cancer pain: barriers and remedies. Supportive Care in Cancer 1993;1(2):74–8.

    Article  PubMed  CAS  Google Scholar 

  128. Green C, Todd KH, Lebovits A, Francis M; American Academy of Pain MedicineCouncil on Ethics. Disparities in pain: ethical issues. Pain Medicine 2006;7(6):530–3.

    Article  PubMed  Google Scholar 

  129. Green CR, Anderson KO, Baker TA, Campbell LC, Decker S, Fillingim RB,Kalauokalani DA, Lasch KE, Myers C, Tait RC, Todd KH, Vallerand AH. The unequal burden of pain: confronting racial and ethnic disparities in pain. Pain Medicine 2003;4(3):277–94.

    Article  PubMed  Google Scholar 

  130. Bandrés E, Zárate R, Ramirez N, Abajo A, Bitarte N, Garíia-Foncillas J. Pharmacogenomics in colorectal cancer: the first step for individualized-therapy. World Journal of Gastroenterology 2007 Nov 28;13(44):5888–901.

    PubMed  Google Scholar 

  131. Mielke S. Individualized pharmacotherapy with paclitaxel. Current Opinion Oncology 2007 Nov;19(6):586–9.

    Article  CAS  Google Scholar 

  132. Rekhadevi PV, Sailaja N, Chandrasekhar M, Mahboob M, Rahman MF, Grover P. Genotoxicity assessment in oncology nurses handling anti-neoplastic drugs. Mutagenesis 2007 Nov;22(6):395–401.

    Article  PubMed  CAS  Google Scholar 

  133. Wang J, Huang Y. Pharmacogenomics of sex difference in chemotherapeutic toxicity. Current Drug Discovery Technology 2007 Jun;4(1):59–68.

    Article  CAS  Google Scholar 

  134. Stoehlmacher J. Prediction of efficacy and side effects of chemotherapy in colorectal cancer. Recent Results in Cancer Research 2007;176:81–8.

    Article  PubMed  CAS  Google Scholar 

  135. Ueno H, Kiyosawa K, Kaniwa N. Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy? British Journal of Cancer 2007 Jul 16;97(2):145–51.

    Article  PubMed  CAS  Google Scholar 

  136. Land SR, Kopec JA, Cecchini RS, Ganz PA, Wieand HS, Colangelo LH, Murphy K, Kuebler JP, Seay TE, Needles BM, Bearden JD 3rd, Colman LK, Lanier KS, Pajon ER Jr, Cella D, Smith RE, O'Connell MJ, Costantino JP, Wolmark N. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. Journal Clinical Oncology 2007;25(16):2205–11.

    Article  CAS  Google Scholar 

  137. Baba H, Doubell TP, Woolf CJ. Peripheral inflammation facilitates Abeta fiber-mediated synaptic input to the substantia gelatinosa of the adult rat spinal cord. Journal of Neuroscience;19(2):859–67.

    Google Scholar 

  138. Dantzer R, Capuron L, Irwin MR, Miller AH, Ollat H, Hugh Perry V, Rousey S, Yirmiya R. Identification and treatment of symptoms associated with inflammation inmedically ill patients. Psychoneuroendocrinology. 2008;33(1):18–29.

    Article  PubMed  Google Scholar 

  139. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW.From inflammation to sickness and depression: when the immune system subjugates the brain. Nature Reviews Neuroscience 2008;9(1):46–56.

    Article  PubMed  CAS  Google Scholar 

  140. Dimsdale JE, Dantzer R. A biological substrate for somatoform disorders: importance of pathophysiology. Psychosomatic Medicine. 2007;69(9):850–4.

    Article  PubMed  Google Scholar 

  141. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nature Reviews Neuroscience. 2008;9(1):46–56.

    Article  PubMed  CAS  Google Scholar 

  142. Dantzer R. Cytokine, sickness behavior, and depression. Neurologic Clinics 2006; 24(3):441–60.

    Article  PubMed  Google Scholar 

  143. Dantzer R, Kelley KW. Twenty years of research on cytokine-induced sickness behavior. Brain, Behavior, and Immunity 2007;21(2):153–60.

    Article  PubMed  CAS  Google Scholar 

  144. Dantzer R. Cytokine, sickness behavior, and depression. Neurologic Clinics 2006;24(3):441–60.

    Article  PubMed  Google Scholar 

  145. Dantzer R. Somatization: a psychoneuroimmune perspective. Psychoneuroendocrinology 2005;30(10):947–52

    Article  PubMed  Google Scholar 

  146. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002 ;420(6917):860–7.

    Article  PubMed  CAS  Google Scholar 

  147. Jan H. Houtveen and Lorenz J.P. van DoornenMedically unexplained symptoms and between-group differences in 24-h ambulatory recording of stress physiology Biological Psychology, Volume 76, Issue 3, October 2007, Pages 239–249

    Article  Google Scholar 

  148. Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain. 1997;69(1–2):1–18.

    Article  PubMed  CAS  Google Scholar 

  149. Matzinger P. Friendly and dangerous signals: is the tissue in control? Nature Immunology 2007 Jan;8(1):11–3.

    Article  PubMed  CAS  Google Scholar 

  150. Matzinger P. The danger model: a renewed sense of self. Science. 2002;296(5566):301–5.

    Article  PubMed  CAS  Google Scholar 

  151. Melzack R, Wall PD. Pain mechanisms: a new theory. Science.1965; 150:971 –9; Reuben SS, Buvanendran A. Preventing the development of chronic pain after orthopaedic surgery with preventive multimodal analgesic techniques. Journal of Bone and Joint Surgergy American. 2007;89(6):1343–58

    Google Scholar 

  152. Apolone G, et al. Pain in Cancer: An outcome research project to evaluate the epidemiology, the quality and the effects of pain treatment in cancer patients. Health and Quality of Life Outcomes 2006;4:7.

    Article  PubMed  Google Scholar 

  153. Ballantyne JC. Chronic Pain Following Treatment for Cancer: The Role of Opioids. Oncologist 2003; 8: 567–575.

    Article  PubMed  Google Scholar 

  154. Kulmatycki KM, Jamali F. Drug disease interactions: role of inflammatory mediators in pain and variability in analgesic drug response. Journal of Pharmacy and Pharmaceutical Sciences 2007;10(4):554–66.

    PubMed  CAS  Google Scholar 

  155. Cleeland CS, Gonin R, Hatfield AK, Edmonson JH, Blum RH, Stewart JA, Pandya KJ. Pain and its treatment in outpatients with metastatic cancer. The New England Journal of Medicine 1994 Mar 3;330(9):592–6.

    Article  PubMed  CAS  Google Scholar 

  156. Visovsky C, Collins M, Abbott L, Aschenbrenner J, Hart C. Putting evidence into practice: evidence-based interventions for chemotherapy-induced peripheral neuropathy. Clinical Journal of Oncology Nursing 2007;11(6):901–13.

    Article  PubMed  Google Scholar 

  157. Cavaletti G, Zanna C. Current status and future prospects for the treatment of chemotherapy-induced peripheral neurotoxicity. European Journal of Cancer 2002;38:1832–1837.

    Article  PubMed  CAS  Google Scholar 

  158. Cavaletti G, Frigeni B, Lanzani F, Piatti M, Rota S, Briani C, Zara G, Plasmati R, Pastorelli F, Caraceni A, Pace A, Manicone M, Lissoni A, Colombo N, Bianchi G, Zanna C; Italian NETox Group. The Total Neuropathy Score as an assessment tool for grading the course ofchemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale. Journal of Peripheral Nervous System 2007 Sep;12(3):210–5.

    Article  Google Scholar 

  159. Cavaletti G, Bogliun G, Marzorati L, Zincone A, Piatti M, Colombo N, Franchi D, La Presa MT, Lissoni A, Buda A, Fei F, Cundari S, Zanna C. Early predictors of peripheral neurotoxicity in cisplatin and paclitaxelcombination chemotherapy. Annals of Oncology 2004 Sep;15(9):1439–42.

    Article  PubMed  CAS  Google Scholar 

  160. Cavaletti G, Bogliun G, Marzorati L, Zincone A, Piatti M, Colombo N, Parma G, Lissoni A, Fei F, Cundari S, Zanna C. Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale. Neurology 2003 Nov 11;61(9):1297–300.

    PubMed  CAS  Google Scholar 

  161. Cavaletti G, Zanna C. Current status and future prospects for the treatment of chemotherapy-induced peripheral neurotoxicity. European Journal of Cancer 2002 Sep;38(14):1832–7

    Article  PubMed  CAS  Google Scholar 

  162. Armstrong T, Almadrones L, Gilbert M. Chemotherapyinduced peripheral neuropathy. Oncology Nursing Forum 2005;32:305–311.

    Article  PubMed  Google Scholar 

  163. Bianchi G, Vitali G, Caraceni A, Ravaglia S, Capri G, Cundari S, et al. Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine. European Journal of Cancer 2005;41:1746–1750.

    Article  PubMed  CAS  Google Scholar 

  164. Bove L, Picardo M, Maresca V, Jandolo B, Pace A. A pilot study on the relation between cisplatin neuropathy and vitamin E. Journal of Experimental and Clinical Cancer Research 2001;20:277–280.

    CAS  Google Scholar 

  165. Cascinu S, Cordella L, Del Ferro E, Fronzoni M, Catalano G. Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: A randomized double-blind placebo-controlled trial. Journal of Clinical Oncology 1995;13:26–32.

    PubMed  CAS  Google Scholar 

  166. Bartolomucci A, Palanza P, Sacerdote P, Panerai AE, Sgoifo A, Openshaw H, Beamon K, Synod TW, Longmate J, Slatkin NE, Doroshaw JH, et al. Neurophysiolgical study of peripheral neuropathy after high-dose paclitaxel: Lack of neuroprotective effect of amifostine. Clinical Cancer Research 2004;10:461–467.

    Article  Google Scholar 

  167. Wolfe GI, Trivedi JR. Painful peripheral neuropathy and its nonsurgical treatment. Muscle and Nerve 2004;30:3–19.

    Article  PubMed  CAS  Google Scholar 

  168. Abuaisha BB, Costanzi JB, Boulton AJ. Acupuncture for the treatment of chronic painful peripheral diabetic neuropathy: A long-term study. Diabetes Research and Clinical Practice 1998;39:115–121.

    Article  PubMed  CAS  Google Scholar 

  169. Almadrones L, Arcot R. Patient guide to peripheral neuropathy. Oncology Nursing Forum 1999;26:1359–1360.

    PubMed  CAS  Google Scholar 

  170. Argyriou AA, Chroni E, Koutras A, Ellul J, Papapetropoulos S, Katsoulas G, et al. Vitamin E for prophylaxis against chemotherapy-induced neuropathy: A randomized controlled trial. Neurology 2005;64:26–31.

    PubMed  CAS  Google Scholar 

  171. Armstrong T, Almadrones L, Gilbert M. Chemotherapy-induced peripheral neuropathy. Oncology Nursing Forum 2005;32:305–311.

    Article  PubMed  Google Scholar 

  172. Arnall DA, Nelson AG, Lopez L, Sanz N, Iversen L, Sanz I, et al. The restorative effects of pulsed infrared light therapy on significant loss of peripheral protective sensation in patients with long-term type 1 and type 2 diabetes mellitus. Acta Diabetologica 2006;43:26–33.

    Article  PubMed  CAS  Google Scholar 

  173. Ashton-Miller J, Yeh M, Richardson JK, Galloway T. A cane reduces loss of balance in patients with peripheral neuropathy: Results from a challenging unipedal balance test. Archives of Physical Medicine and Rehabilitation 1996;77:446–452.

    Article  PubMed  CAS  Google Scholar 

  174. Balducci S, Iacobellis G, Parisi L, Di Biase N, Calandriello E, Leonetti F, et al. Exercise training can modify the natural history of diabetic peripheral neuropathy. Journal of Diabetes and Its Complications 2006;20:216–223.

    Article  PubMed  Google Scholar 

  175. Bianchi G, Vitali G, Caraceni A, Ravaglia S, Capri G, Cundari S, et al. Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine. European Journal of Cancer 2005;41:1746–1750.

    Article  PubMed  CAS  Google Scholar 

  176. Bove L, Picardo M, Maresca V, Jandolo B, Pace A. A pilot study on the relation between cisplatin neuropathy and vitamin E. Journal of Experimental and Clinical Cancer Research 2001;20:277–280.

    CAS  Google Scholar 

  177. Cascinu S, Catalano V, Cordella L, Labianca R, Giordani P, Baldelli AM, et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: A randomized, double-blind, placebo-controlled trial. Journal of Clinical Oncology 2002;20:3478–3483.

    Article  PubMed  CAS  Google Scholar 

  178. Cascinu S, Cordella L, Del Ferro E, Fronzoni M, Catalano G. Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: A randomized double-blind placebo-controlled trial. Journal of Clinical Oncology 1995;13:26–32.

    PubMed  CAS  Google Scholar 

  179. Cata JP, Cordella JV, Burton AW, Hassenbusch SJ, Weng HR, Dougherty PM. Spinal cord stimulation relieves chemotherapy-induced pain: A clinical case report. Journal of Pain and Symptom Management 2004;27:72–78.

    Article  PubMed  Google Scholar 

  180. Davis ID, Kiers L, MacGregor L, Quinn M, Arezzo J, Green M, et al. A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy. Clinical Cancer Research 2005;11:1890–1898.

    Article  PubMed  CAS  Google Scholar 

  181. Eckel F, Schmelz R, Adelsberger H, Erdmann J, Quasthoff S, Lersch C. [Prevention of oxaliplatin-induced neuropathy by carbamazepine. A pilot study.] Deutsche Medizinische Wochenschrift 2002;127:78–82.

    Article  PubMed  CAS  Google Scholar 

  182. Hammack J, Michalak J, Loprinzi C, Sloan J, Novotny P, Soori G, et al. Phase III evaluation of nortriptyline for alleviation of symptoms of cisplatinum-induced peripheral neuropathy. Pain 2002;98:195–203.

    Article  PubMed  CAS  Google Scholar 

  183. Hilpert F, Stahle A, Tome O, Burges A, Rossner D, Spathe K, et al. Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy. A double blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynakologische Onkologoie (AGO) Ovarian Cancer Study Group. Supportive Care in Cancer 2005;13:797–805.

    Article  PubMed  CAS  Google Scholar 

  184. Jiang H, Shi K, Li X, Zhou W, Cao Y. Clinical study on the wrist-ankle acupuncture treatment for 30 cases of diabetic peripheral neuritis. Journal of Traditional Chinese Medicine 2006;26:8–12.

    PubMed  Google Scholar 

  185. Forst T, Nguyen M, Forst S, Disselhoff B, Pohlmann T, Pfutzner A. Impact of low frequency transcutaneous electrical nerve stimulation on symptomatic diabetic neuropathy using the new Salutaris device. Diabetes, Nutrition and Metabolism 2004;17:163–168.

    PubMed  CAS  Google Scholar 

  186. Forst T, Pohlmann T, Kunt T, Goitom K, Schulz G, Lobig M, et al. The influence of local capsaicin treatment on small nerve fibre function and neurovascular control in symptomatic diabetic neuropathy. Acta Diabetologica 2002;39:1–6.

    Article  PubMed  CAS  Google Scholar 

  187. Phillips KD, Skelton WD, Hand GA. Effect of acupuncture administered in a group setting on pain and subjective peripheral neuropathy in persons with human immunodeficiency virus disease. Journal of Alternative and Complementary Medicine 2004;10:449–455.

    Article  Google Scholar 

  188. Prendergast JJ, Miranda G, Sanchez M. Improvement of sensory impairment in patients with peripheral neuropathy. Endocrine Practice 2004;10:24–30.

    PubMed  Google Scholar 

  189. Reichstein L, Labrenz S, Ziegler D, Martin S. Effective treatment of symptomatic diabetic polyneuropathy by high-frequency external muscle stimulation. Diabetologia 2005;48:824–828.

    Article  PubMed  CAS  Google Scholar 

  190. Gamelin L, Boisdron-Celle M, Delva R, Geurin-Meyer V, Ifrah N, Morel A, et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: A retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clinical Cancer Research 2004;10:4055–4061.

    Article  PubMed  CAS  Google Scholar 

  191. Leonard DR, Farooqi MH, Myers S. Restoration of sensation, reduced pain, and improved balance in subjects with diabetic peripheral neuropathy: A double-blind, randomized, placebo-controlled study with monochromatic near-infrared treatment. Diabetes Care 2004;27:168–172.

    Article  PubMed  Google Scholar 

  192. Lindeman E, Leffers P, Spaans F, Drukker J, Reulen J, Kerckhoffs M, et al. Strength training in patients with myotonic dystrophy and hereditary motor and sensory neuropathy: A randomized clinical trial. Archives of Physical Medicine and Rehabilitation 1995;76:612–620.

    Article  PubMed  CAS  Google Scholar 

  193. Maestri A, De Pasquale Ceratti A, Cundari S, Zanna C, Cortesi E, Crino L. A pilot study on the effect of acetyl-L-carnitine in paclitaxel- and cisplatin-induced peripheral neuropathy. Tumori 2005;91:135–138.

    PubMed  CAS  Google Scholar 

  194. Marrs J, Newton S. Updating your peripheral neuropathy “know how.” Clinical Journal of Oncology Nursing 2003;7:299–303.

    Article  PubMed  Google Scholar 

  195. Moore D, Donnelly J, McGuire WP, Almadrones L, Cella DF, Herzog TJ, et al. Limited access trial using amifostine for protection against cisplatin and three hour paclitaxel-induced neurotoxicity: A phase II study of the Gynecologic Oncology Group. Journal of Clinical Oncology 2003;21:4207–4213.

    Article  PubMed  CAS  Google Scholar 

  196. Pace A, Savarese A, Picardo M, Maresca V, Pacetti U, Del Monte G, et al. Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. Journal of Clinical Oncology 2003;21:927–931.

    Article  PubMed  CAS  Google Scholar 

  197. Richardson JK, Sandman D, Vela S. A focused exercise regimen improves clinical measures of balance in patients with peripheral neuropathy. Archives of Physical Medicine and Rehabilitation 2001;82:205–209.

    Article  PubMed  CAS  Google Scholar 

  198. Richardson JK, Thies S, DeMott T, Ashton-Miller JA. Interventions improve gait regularity in patients with peripheral neuropathy while walking on an irregular surface under low light. Journal of the American Geriatrics Society 2004;52:510–515.

    Article  PubMed  Google Scholar 

  199. Shlay JC, Chaloner K, Max MB, Flaws B, Reichelderfer P, Wentworth D, et al. Acupuncture and amitriptyline for pain due to HIV-related peripheral neuropathy: A randomized controlled trial. JAMA 1998;280:1590–1595.

    Article  PubMed  CAS  Google Scholar 

  200. Smyth JF, Bowman A, Perren T, Wilkinson P, Prescott RJ, Quinn KJ, et al. Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: Results of a double-blind, randomized trial Annals of Oncology 1997;8:569–573.

    Article  PubMed  CAS  Google Scholar 

  201. Stubblefield MD, Vahdat LT, Balmaceda AB, Troxel AB, Hesdorffer CS, Gooch CL. Glutamine as a neuroprotective agent in high-dose paclitaxel-induced peripheral neuropathy: A clinical and electrophysiologic study. Clinical Oncology 2005;17:271–276.

    Article  PubMed  CAS  Google Scholar 

  202. Vahdat L, Papadopoulos K, Lange D, Leuin S, Kaufman E, Donovan D, et al. Reduction of paclitaxel-induced peripheral neuropathy with glutamine. Clinical Cancer Research 2001;7:1192–1197.

    PubMed  CAS  Google Scholar 

  203. Weijl NI, Hopman GD, Wipkink-Bakker A, Lentjes EG, Berger HM, Cleton FJ, et al. Cisplatin combination chemotherapy induces a fall in plasma antioxidants of cancer patients. Annals of Oncology 1998;9:1331–1337.

    Article  PubMed  CAS  Google Scholar 

  204. White CM, Pritchard J, Turner-Stokes L. Exercise for people with peripheral neuropathy. Cochrane Database of Systematic Reviews 2004;4. Art. No.: CD003904. DOI: 10.1002/14651858.CD003904.pub2.

    Google Scholar 

  205. Wong R, Sagar S. Acupuncture treatment for chemotherapy-induced peripheral neuropathy—A case series. Acupuncture in Medicine 2006;24(2):87–91

    Article  PubMed  Google Scholar 

  206. Pace A, Savarese A, Picardo M, Maresca V, Pacetti U, Del Monte G, et al. Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. Journal of Clinical Oncology 2003;21:927–931.

    Article  PubMed  CAS  Google Scholar 

  207. Phillips KD, Skelton WD, Hand GA. Effect of acupuncture administered in a group setting on pain and subjective peripheral neuropathy in persons with human immunodeficiency virus disease. Journal of Alternative and Complementary Medicine 2004;10:449–455.

    Article  Google Scholar 

  208. Reichstein L, Labrenz S, Ziegler D, Martin S. Effective treatment of symptomatic diabetic polyneuropathy by high-frequency external muscle stimulation. Diabetologia 2005;48:824–828.

    Article  PubMed  CAS  Google Scholar 

  209. Richardson JK, Sandman D, Vela S. A focused exercise regimen improves clinical measures of balance in patients with peripheral neuropathy. Archives of Physical Medicine and Rehabilitation 2001;82:205–209.

    Article  PubMed  CAS  Google Scholar 

  210. Richardson JK, Thies S, DeMott T, Ashton-Miller JA. Interventions improve gait regularity in patients with peripheral neuropathy while walking on an irregular surface under low light. Journal of the American Geriatrics Society 2004;52:510–515.

    Article  PubMed  Google Scholar 

  211. Shlay JC, Chaloner K, Max MB, Flaws B, Reichelderfer P, Wentworth D, et al. Acupuncture and amitriptyline for pain due to HIV-related peripheral neuropathy: A randomized controlled trial. JAMA 1998;280:1590–1595.

    Article  PubMed  CAS  Google Scholar 

  212. Smyth JF, Bowman A, Perren T, Wilkinson P, Prescott RJ, Quinn KJ, et al. Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: Results of a double-blind, randomized trial. Annals of Oncology 1997;8:569–573.

    Article  PubMed  CAS  Google Scholar 

  213. Stubblefield MD, Vahdat LT, Balmaceda AB, Troxel AB, Hesdorffer CS, Gooch CL. Glutamine as a neuroprotective agent in high-dose paclitaxel-induced peripheral neuropathy: A clinical and electrophysiologic study. Clinical Oncology 2005;17:271–276.

    Article  PubMed  CAS  Google Scholar 

  214. Vahdat L, Papadopoulos K, Lange D, Leuin S, Kaufman E, Donovan D, et al. Reduction of paclitaxel-induced peripheral neuropathy with glutamine. Clinical Cancer Research 2001;7:1192–1197.

    PubMed  CAS  Google Scholar 

  215. Weijl NI, Hopman GD, Wipkink-Bakker A, Lentjes EG, Berger HM, Cleton FJ, et al. Cisplatin combination chemotherapy induces a fall in plasma antioxidants of cancer patients. Annals of Oncology 1998;9:1331–1337.

    Article  PubMed  CAS  Google Scholar 

  216. Reuben SS, Buvanendran A. Preventing the development of chronic pain after orthopaedic surgery with preventive multimodal analgesic techniques. Journal of Bone and Joint Surgery America. 2007;89(6):1343–58.

    Article  Google Scholar 

  217. Coderre TJ, Katz J, Vaccarino AL, Melzack R. Contribution of central neuroplasticity to pathological pain: review of clinical and experimental evidence. Pain1993;52:259–85

    Article  PubMed  CAS  Google Scholar 

  218. Flor H, Nikolajsen L, Staehelin Jensen T. Phantom limb pain: a case of maladaptive CNS plasticity? Nature Reviews Neuroscience 2006 Nov;7(11):873–81.

    Article  PubMed  CAS  Google Scholar 

  219. Woolf CJ, Salter MW. Neuronal plasticity: increasing the gain in pain. Science 2000; 288:1765–1769.

    Article  PubMed  CAS  Google Scholar 

  220. Perkins FM, Kehlet H. Chronic pain as an outcome of surgery. A review of predictive factors. Anesthesiology 2000;93:1123–1133.

    Article  PubMed  CAS  Google Scholar 

  221. Macrae WM, Davies HTO. Chronic postsurgical pain. In: Crombie IK, Croft PR, Linton SJ, Leresche L, Von Korff, M, editors. Epidemiology of pain: a report on the Task Force on Epidemiology. Seattle: IASP Press; 1999. pp. 125–142.

    Google Scholar 

  222. Diatchenko L, Slade GD, Nackley AG, Bhalang K, Sigurdsson A, Belfer I, Goldman D, Xu K, Shabalina SA, Shagin D, Max MB, Makarov SS, Maixner W. Genetc basis for individual variations in pain perception and the development of a chronic pain condition. Human Molecular Genetics 2005;14:135–43.

    Article  CAS  Google Scholar 

  223. Eisenberg E. Post-surgical neuralgia. Pain 2004;111:3–7; Melzack R, Wall PD. Pain mechanisms: a new theory. Science 1965; 150:971 –

    Google Scholar 

  224. Shavit Y, Fridel K, Beilin B. Postoperative pain management and proinflammatory cytokines: animal and human studies. Journal of Neuroimmune Pharmacology 2006 Dec;1(4):443–51.

    Article  PubMed  Google Scholar 

  225. Seruga B, Zhang H, Bernstein LJ, Tannock IF. Cytokines and their relationship to the symptoms and outcome of cancer. Nature Reviews Cancer 2008 Oct 10. [Epub ahead of print].

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. National Cancer Institute, SRLB/DEA, National Institutes of Health, 6116 Executive Boulevard, Rockville, MD 20852-8329, USA

    Rhonda J. Moore

Authors
  1. Rhonda J. Moore
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rhonda J. Moore .

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Moore, R.J. (2009). Chemotherapy Induced Peripheral Neuropathies (CIPNs): A Biobehavioral Approach. In: Biobehavioral Approaches to Pain. Springer, New York, NY. https://doi.org/10.1007/978-0-387-78323-9_11

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-78323-9_11

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-78322-2

  • Online ISBN: 978-0-387-78323-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation